Mainz, Germany

Monika Hofmann

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Boehringer Ingelheim Pharma Gmbh & Co Kg. Active years: 2009-2011.


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2009-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Monika Hofmann: Innovator in Pharmaceutical Chemistry

Introduction

Monika Hofmann is a distinguished inventor based in Mainz, Germany. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative processes for drug formulation. With a total of 2 patents to her name, Hofmann's work has had a notable impact on the industry.

Latest Patents

Hofmann's latest patents include a method for preparing tiotropium salts. This invention relates to a new process for preparing tiotropium salts of general formula 1, wherein X may have the meanings given in the claims and in the specification. This innovative approach enhances the efficiency and effectiveness of tiotropium salt production, which is crucial for respiratory therapies.

Career Highlights

Monika Hofmann is currently employed at Boehringer Ingelheim Pharma GmbH & Co. KG, a leading global pharmaceutical company. Her role involves extensive research and development, focusing on improving drug formulations and processes. Hofmann's expertise in pharmaceutical chemistry has positioned her as a key player in her field.

Collaborations

Throughout her career, Hofmann has collaborated with notable colleagues, including Ralf Lock and Werner Belzer. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Monika Hofmann's contributions to pharmaceutical chemistry through her patents and collaborations highlight her role as an influential inventor. Her work continues to advance the field and improve therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…